PALI— PALISADE BIO, INC.

MaterialsBiotechnology$366M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$10.2M+12.5%	$9.1M+31.5%	$6.9M+5.3%	$6.5M
General and administrative	$7.9M+35.7%	$5.8M-6.5%	$6.2M-29.2%	$8.8M
Total operating expenses	$18.1M+21.5%	$14.9M+11.6%	$13.3M-15.3%	$15.7M
Loss from operations	-$18.1M-21.5%	-$14.9M-13.7%	-$13.1M+16.9%	-$15.7M
Interest expense	-$10K+16.7%	-$12K+20.0%	-$15K-15.4%	-$13K
Other income, net	$1.3M+196.8%	$433K-44.8%	$785K-69.6%	$2.6M
Total other income, net	$1.3M+202.9%	$421K-45.3%	$770K-47.3%	$1.5M
Net loss	-$16.8M-16.2%	-$14.4M-17.4%	-$12.3M+13.7%	-$14.3M
Basic weighted average shares used in computing net loss per common share	$55669821.00+3830.2%	$1416471.00+210.6%	$456014.00-99.9%	$880311000.00
Diluted weighted average shares used in computing net loss per common share	$55669821.00+3830.2%	$1416471.00-79.3%	$6840213.00-99.2%	$880311000.00
Basic net loss per common share	-$0.30+97.1%	-$10.19+62.3%	-$27.01-63.4%	-$16.53
Diluted net loss per common share	-$0.30+97.1%	-$10.19+62.3%	-$27.01+99.8%	-$16530.00

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.